PubMed Health⌕ Search

Biomedical subjects

R D Schultz

Publications and source records attributed to R D Schultz.

At least 19 recordsLinked to original sources
PubMed2006

Effect of recombinant canine distemper vaccine on antibody titers in previously vaccinated dogs.

Two canine distemper virus (CDV) vaccine types are currently commercially available: modified-live virus (MLV) vaccines and a canarypox recombinant CDV (rCDV) vaccine (Recombitek, Merial). This study compared the ability of the rCDV vaccine and MLV vaccines to significantly enhance (boost) the antibody response of previously immunized adult and juvenile dogs. A significant (fourfold or greater) increase in titer occurred in significantly more dogs revaccinated with Recombitek C-4 or Recombitek C-6 than with the MLV-CDV vaccines. This study demonstrates that Recombitek, the only vaccine for dogs containing rCDV, is more likely to significantly boost the CDV antibody response in previously vaccinated dogs than are the MLV-CDV vaccines. Because rCDV vaccine can boost the antibody titer of dogs previously vaccinated with an MLV vaccine, it can and should be used when core vaccines are readministered.

Animals↗
PubMed2006

Effect of vaccination with recombinant canine distemper virus vaccine immediately before exposure under shelter-like conditions.

Vaccination with modified-live virus (MLV) canine distemper virus (CDV) vaccine has historically been recommended for animals in high-risk environments because of the rapid onset of immunity following vaccination. Recombinant CDV (rCDV) vaccine was deemed a suitable alternative to MLV-CDV vaccination in pet dogs, but insufficient data precluded its use where CDV was a serious threat to puppies, such as in shelters, kennels, and pet stores. In this study, dogs experimentally challenged hours after a single dose of rCDV or MLV vaccine became sick but recovered, whereas unvaccinated dogs became sick and died. Dogs vaccinated with a single dose of rCDV or MLV vaccine 1 week before being experimentally challenged remained healthy and showed no clinical signs. Dogs given one dose of rCDV vaccine hours before being placed in a CDV-contaminated environment did not become sick. These findings support the hypothesis that rCDV vaccine has a similar time-to-immunity as MLV-CDV vaccines and can likewise protect dogs in high-risk environments after one dose.

Animals↗
PubMed2002

Cats differ from mink and ferrets in their response to commercial vaccines: a histologic comparison of early vaccine reactions.

Early histologic changes in lesions at vaccine sites were compared in cats, mink, and ferrets. Twenty-four 4-month-old cats, 20 4-month-old mink, and 20 12-month-old ferrets were vaccinated with three rabies virus vaccines, two feline leukemia virus vaccines, alum adjuvant, and saline. Injection sites were excised at selected time points up to 21 days postvaccination. Histologic examination of the tissue revealed significant differences among the cats, mink, and ferrets in the local response to the commercial vaccines. When compared with ferrets and mink, cats had more lymphocytes in response to all three rabies vaccines. Production of fibroblasts, collagen, and macrophages differed among the three killed aluminum-adjuvanted vaccines in cats but did not differ significantly in mink or ferrets. Cats produced fewer binucleate cells than did mink or ferrets in response to the two adjuvanted leukemia virus vaccines. Differences seen in early tissue response of cats to commercial vaccines may be related to the increased predisposition of cats to vaccine-associated sarcomas.

Animals↗
PubMed2001

Canine vaccination.

New technologies for vaccine development and infectious disease diagnosis are likely to be introduced in the near future. With this new technology comes the opportunity to vaccinate companion animals against even more infectious agents than is currently practiced in the United States. As we look forward, it becomes particularly important to review current vaccination standards applied to dogs with respect to current knowledge of duration of immunity, awareness of incidence, and likelihood of injurious or even fatal adverse events associated with vaccination, and individual risk factors that dictate which vaccines are most appropriate at which stage of life.

Animals↗
PubMed2000

Serologic survey for selected infectious disease agents in swift and kit foxes from the western United States.

A serologic survey of swift fox (Vulpes velox) and kit fox (V. macrotis) from the western USA was conducted for 12 infectious diseases. Samples from swift fox were collected between 1987 and 1992 from Colorado (n = 44), Kansas (n = 10), and Wyoming (n = 9). Samples from kit fox were collected in California (n = 86), New Mexico (n = 18), Utah (n = 9), and Arizona (n = 6). Overall antibody prevalence rates were 33 of 110 (30%) for canine parvovirus (CPV), 9 of 72 (13%) for canine distemper virus (CDV), 23 of 117 (20%) for vesicular stomatitis New Jersey, 16 of 117 (14%) for vesicular stomatitis Indiana, six of 117 (5%) for Cache Valley virus, five of 117 (4%) for Jamestown Canyon virus, one of 97 (1%) for rabies virus, one of 117 (1%) for Colorado tick fever virus, and one of 117 (1%) for western equine encephalitis virus. In addition, antibodies were not found to Yersinia pestis, Francisella tularensis, and Borrelia burgdorferi in serum from 25 Colorado swift fox. Adult swift fox from Colorado had serologic evidence of exposure to CPV more often than juveniles. No juvenile swift fox from Colorado had serum antibodies to CDV. There were season-specific differences in serum antibody prevalence for CPV for swift fox from Colorado. No viruses were isolated from ectoparasites or fox from Colorado.

Animals↗
PubMed1998

Growth hormone receptor and regulation of gene expression in fetal lymphoid cells.

The role of growth hormone (GH) in modulating the adult immune response is receiving increased attention; however, its role in the development of immune competence in the fetus has not been defined. In order to begin to address the role of GH in the ontogeny of the immune response. cells from bovine fetal spleen and thymus were examined for GH receptor and responsiveness to GH. Northern analysis and ligand binding studies showed that growth hormone receptor (GHR) was readily detected in early- and mid-gestational fetal thymocytes, but it was less readily detected in thymocytes from older fetuses. In contrast, GHR was easily detected in splenocytes at all fetal ages. Thymocytes and splenocytes from mid-gestational fetuses expressed low levels of cell surface GHR by flow cytofluorometric analysis, and CD4+ and CD8 (single positive) thymocyte subsets were positive. Northern analyses were employed to determine the effects of in vitro GH treatment on expression of several proto-oncogenes, cytokines, and GHR in thymocytes from fetuses at approximately mid-gestation. GH treatment for 30 min down-regulated c-jun and c-fos mRNA approximately 2- and 2.8-fold, respectively. After 6 h treatment, GH increased transcript levels for interleukin (IL)-1alpha, IL-1beta, IL-6, and GM-CSF about 2.5-, 2.2-, 3-, and 2-fold, respectively. GH also down-regulated the expression of its own receptor about 3.2-fold after 8 h of incubation. The presence of GHR in fetal lymphoid cells and its temporal and spatial regulation suggest a potential role for GH in the development and or function of the fetal bovine immune system. Although the mechanism(s) is unclear, our results suggest that GH is intimately involved in lymphocyte function and expression of certain cytokines during a critical period of fetal immune development.

Animals↗
PubMed1997

Growth hormone and Pit-1 expression in bovine fetal lymphoid cells.

Bovine fetal lymphoid cells were examined for growth hormone (GH) and the transcription factor Pit-1/GHF-1 mRNA. GH and Pit-1/GHF-1 transcripts were detected in thymocytes and splenocytes from fetuses at 60, 90, 120, and 270 d of gestation using reverse transcription-polymerase chain reaction (RT-PCR). Northern analysis indicated that the lymphoid GH mRNA was approximately 350 nucleotides larger than in the pituitary. RT-PCR analysis demonstrated that the coding regions as well as 3' untranslated region of the lymphocyte GH and pituitary transcripts were the same. Analysis of the 5'-untranslated region of the lymphocyte GH mRNA showed that transcription began upstream from the start site in the pituitary gland, suggesting differences in regulation in these tissues. Fetal thymocytes and splenocytes expressed Pit-1/GHF-1 mRNA; however, they contained only the 2.5-kb transcript. The GH and Pit-1/GHF-1 mRNA in fetal lymphoid cells supports the hypothesis that lymphocyte-derived GH may function as an autocrine and/or paracrine factor during the development and maturation of the bovine fetal immune system.

Animals↗
PubMed1997

Serological survey for diseases in free-ranging coyotes (Canis latrans) in Yellowstone National Park, Wyoming.

From October 1989 to June 1993, we captured and sampled 110 coyotes (Canis latrans) for various diseases in Yellowstone National Park, Wyoming (USA). Prevalence of antibodies against canine parvovirus (CPV) was 100% for adults (> 24 months old), 100% for yearlings (12 to 24 months old), and 100% for old pups (4 to 12 months old); 0% of the young pups (< 3 months old) had antibodies against CPV. Presence of antibodies against canine distemper virus (CDV) was associated with the age of the coyote, with 88%, 54%, 23%, and 0% prevalence among adults, yearlings, old pups, and young pups, respectively. Prevalence of CDV antibodies declined over time from 100% in 1989 to 33% in 1992. The prevalence of canine infectious hepatitis (ICH) virus antibodies was 97%, 82%, 54%, and 33%, for adults, yearlings, old pups, and young pups, respectively. The percentage of coyotes with ICH virus antibodies also declined over time from a high of 100% in 1989 to 31% in 1992, and 42% in 1993. Prevalence of antibodies against Yersinia pestis was 86%, 33%, 80%, and 7%, for adults, yearlings, old pups, and young pups, respectively, and changed over time from 57% in 1991 to 0% in 1993. The prevalence of antibodies against Francisella tularensis was 21%, 17%, 10%, and 20%, for adults, yearlings, old pups, and young pups, respectively. No coyotes had serologic evidence of exposure to brucellosis, either Brucella abortus or Brucella canis. No coyotes were seropositive to Leptospira interrogans (serovars canicola, hardjo, and icterohemorrhagiae). Prevalence of antibodies against L. interrogans serovar pomona was 7%, 0%, 0%, and 9%, for adults, yearlings, old pups, and young pups, respectively. Antibodies against L. interrogans serovar grippotyphosa were present in 17% of adults and 0% of yearlings, old pups, and young pups. Many infectious canine pathogens (CPV, CDV, ICH virus) are prevalent in coyotes in Yellowstone National Park, with CPV influencing coyote pup survival during the first 3 months of life; eight of 21 transmitted pups died of CPV infection in 1992. The potential impact of these canine pathogens on wolves (C. lupus) reintroduced to Yellowstone National Park remains to be documented.

Adenoviruses, Canine↗
PubMed1997

Comparison of selected canine vaccines for their ability to induce protective immunity against canine parvovirus infection.

OBJECTIVE: To compare the ability of 6 commercially available multicomponent canine vaccines to stimulate antibody production in pups with variable amounts of maternally derived canine parvovirus (CPV) antibody and to induce protective immunity against challenge exposure. ANIMALS: Sixty-three 5- to 6-week-old Beagle pups with passively acquired CPV antibody titer between 1: 20 and 1:320. PROCEDURE: 9 pups were assigned to each of 6 vaccine groups and 1 control group. Eight pups in each group were inoculated with vaccine or saline solution twice, with 3 weeks between administrations. The ninth pup served as an uninoculated contact control. Serum samples were obtained weekly and tested for CPV antibody by hemagglutination-inhibition assay. All pups were challenge exposed with virulent CPV-2a and CPV-2b at 14 to 15 weeks of age. RESULTS: 3 of the vaccines failed to provide protective immunity against challenge exposure because all pups in these groups became infected and most died. A fourth vaccine protected against death, but not infection and disease. Two of the 6 vaccines induced an immune response that was protective against infection and disease. CONCLUSION AND CLINICAL RELEVANCE: Substantial differences existed among commercial vaccines available in 1994 in their ability to immunize pups with maternally derived CPV antibody. These differences caused many vaccinated pups to be susceptible to CPV disease for variable periods because some vaccines failed to immunize. Importantly, all 4 of the vaccines that performed poorly have recently been replaced by more effective products so that the 6 vaccines now perform similarly.

Aging↗
PubMed1996

Wild type p53 reduces the size of tumors caused by bovine leukemia virus-infected cells.

Bat lung (BAT(2)CL6) cells infected with bovine leukemia virus (BLV) cause malignant tumors in nude mice that after 6 weeks subcutaneous growth, have an average volume of 0.3m(3). Uninfected bat lung cells (Tb 1 Lu) produce small benign neoplasms that average 0.003 cm(3). BAT(2)CL6 cells were transfected in vitro with expression vectors that produce wild type human or mutant p53. Production of human p53 in transfected BAT(2)CL6 cells was confirmed by immunoprecipitation of p53 and by immunohistochemical staining using anti-human p53 monoclonal antibodies. BAT(2)CL6 cells transfected with wild type p53 produced tumors in nude mice averaging 0.03 cm(3) whereas cells transfected with mutant p53 yielded tumors averaging 0.3cm(3). BAT(2)CL6 cell tumors after 1 week subcutaneous growth were transfected in situ with the wild type p53 gene. At 6 weeks tumor volume of in situ transfected tumors was similar to those resulting from cells transfected in vitro. Histopathologic examination and immunochemical staining of tumors produced in nude mice after wild type p53 treatment showed no significant differences when compared to tumors produced by untreated BAT(2)CL6 cells. Therefore, it is likely that the tumors produced by p53 treated-cells arose from cells that escaped transfection. The reduction of tumor size by restoration of wild type 53 may prove to be a useful therapy for BLV-induced tumors.

Animals↗
PubMed1996

Use of c7E3 Fab in conjunction with primary coronary stenting for acute myocardial infarctions complicated by cardiogenic shock.

Although use of thrombolytic therapy during primary angioplasty is controversial, the development of a monoclonal antibody (c7E3 Fab) to the platelet glycoprotein IIb/IIIa receptor has been a tremendous breakthrough in the field of interventional cardiology. Use of the antibody during high-risk angioplasty or atherectomy procedures has been shown to significantly reduce the incidence of death, MI, or emergent repeat revascularization. We describe four cases in which c7E3 Fab was used as an adjunct to coronary stenting in the peri-infarct period in patients with cardiogenic shock. To our knowledge, no other reports have addressed the use of glycoprotein IIb/IIIa receptor inhibitors with coronary stent implantation. Our experience in this small population suggests that coronary stenting for myocardial infarctions may be a feasible option in selected patients to allow maximal luminal dilation and successful reperfusion. We emphasize that our results are preliminary, and we eagerly await the results of the EPILOG study which will provide more definitive data on the safety and efficacy of c7E3 Fab and coronary stenting from the perspective of a large, randomized trial.

Abciximab↗
PubMed1996

Viral status and antibody response in cattle inoculated with recombinant bovine leukemia virus-vaccinia virus vaccines after challenge exposure with bovine leukemia virus-infected lymphocytes.

OBJECTIVE: To determine the bovine leukemia virus (BLV) antibody response and infectivity status in BLV-vaccinated cattle after challenge exposure with BLV-infected lymphocytes. DESIGN: Steers were inoculated with vaccinia virus constructs expressing the gag, pol, and env genes of the BLV or the env gene only of the BLV genome, then challenge exposed with BLV-infected lymphocytes. The steers' BLV antibody and infectivity status was monitored. ANIMALS: Fifteen 8- to 9-month-old Holstein steers previously determined to be BLV antibody and BLV negative. PROCEDURE: 1 month after second after inoculation, steers were challenge exposed with 10(6) BLV-infected lymphocytes from a highly infective BLV-positive cow. Serum and blood lymphocytes were obtained regularly for 6 months. The agar gel immunodiffusion assay, ELISA, and serum neutralization assay were used to detect BLV antibody in serum of steers. The sheep infectivity and syncytium-forming assays were used to determine the viral status of the steers. RESULTS: Differences were seen in antibody responses between the BLV-vaccinated and non-BLV-vaccinated control groups. All cattle were susceptible to infection when challenge exposed with BLV-infected lymphocytes. CONCLUSION: Despite the enhanced immune response in the BLV-vaccinated cattle after challenge exposure, none of the BLV-vaccinated cattle was protected from BLV infection. CLINICAL RELEVANCE: Vaccination is not an effective way to protect cattle from BLV infection.

Animals↗
PubMed1995

Temporal stability of the virus load of cattle infected with bovine leukemia virus.

The relative virus load of bovine leukemia virus (BLV) infected cattle was measured by an immunoperoxidase infectivity assay (IPIA), and by immunoperoxidase staining of cultured leukocytes using a monoclonal antibody to the capsid protein (p24) of BLV. The results of paired sample data taken at different time points spanning 2-3 years show that BLV-infected cattle are stable regarding the amount of BLV produced by their peripheral blood mononuclear cells (PBMCs). Spearman's Rank Correlation demonstrated significant relationships between data from individual cattle taken at four different time points. In addition, this study documents the large range of variation in the virus load of individual cattle.

Animals↗
PubMed1994

Stabilization of the p53 gene product in two bovine leukemia virus infected cell lines.

Fetal lamb kidney cells (FLK) and bat lung (BAT2CL6) cells that continuously produce bovine leukemia virus (BLV) were found to cause malignant tumors in nude mice. Uninfected bat lung cells (Tb 1 Lu) produced a small benign neoplasm. Pulse chase studies showed that the p53 gene product in BAT2CL6 cells was more stable compared with p53 in Tb 1 Lu cells. Mono-clonal antibody studies suggested that a mutant form of the p53 protein was produced in BLV-infected cells. Heteroduplex mapping studies of the p53 gene from BLV-infected cells also suggested that a mutation in p53 had occurred. Stabilization of the p53 gene product in BLV-infected cells may contribute to the progression of tumor virulence.

Animals↗
PubMed1994

Primary IgG secreting plasma cell tumor in the gastrointestinal tract of a dog.

A mixed-breed dog, evaluated because of a chronic history of diarrhea and intestinal bleeding, was found to have a multilobular mass involving the intestine. Surgical resection of the mass necessitated an ileocolic anastomosis. On the basis of histologic and electron microscopic appearance and staining characteristics, a tentative diagnosis of intestinal carcinoid was made. Recovery was uncomplicated; the owners declined further diagnostic tests or treatment. Eight weeks later, the dog was reexamined because of signs consistent with hyperviscosity syndrome and hyperproteinemia. At the owner's request, the dog was euthanatized. At necropsy, extensive metastases to liver and lymph nodes, but not to bone, were seen. Reevaluation of the intestinal mass supported classifying the tumor as an IgG-secreting extramedullary plasmacytoma. This case underscores the need for additional histologic techniques, especially when confronted with an unusual manifestation of hyperproteinemia.

Animals↗
PubMed1994

Evidence for bovine leukemia virus in mammary epithelial cells of infected cows.

BACKGROUND: Bovine leukemia virus (BLV), a retrovirus, usually causes a subclinical infection of dairy and beef cattle, but in < 1% of infected cattle a B cell lymphoma may develop after several years of infection. BLV is transmitted horizontally among cattle, and infected animals have anti-BLV titers. Expression of BLV antigen, however, is silent in peripheral blood lymphocytes in vivo. The tropism of BLV has been assumed to be limited to B lymphocytes, because no other cell type has been found to harbor the virus in vivo. Since retrovirus-like particles had been identified in milk, and infection can be transmitted by milk, we decided to investigate whether BLV was in mammary epithelial cells. EXPERIMENTAL DESIGN: Pure cultures of mammary epithelial cells were established from cells shed into the milk of 28 cows. BLV was searched in these cultures by immunocytochemistry and the polymerase chain reaction, the specificity of the latter confirmed by Southern blot hybridization and DNA sequencing. BLV was searched immunocytochemically in mammary tissue sections from 12 cows. RESULTS: Antigenic and/or molecular evidence of BLV was found in the cultured cells of 20 cows. Antigenic evidence of BLV was found in tissue sections from 10 cows, indicating virus expression in vivo. Simultaneous detection of BLV p24 and cytokeratins, localized antigen expression to the mammary epithelial cells. CONCLUSIONS: These indications of BLV in mammary epithelial cells in vivo suggest that BLV is capable of infecting and expressing antigen in glandular epithelium in vivo and has a broader tissue tropism than was previously thought. They raise the question of how persistent mammary infection by BLV may influence the course of bovine lymphoma, and what effect the virus may have on the mammary gland.

Animals↗
PubMed1993

Suppressive effect of serum from pigs and dogs fed a diet deficient in vitamin E and selenium on lymphocyte proliferation.

The effect of sera collected from either pigs or dogs previously fed a vitamin E (vit E)- and selenium (Se)-deficient diet on in vitro lymphocyte blastogenesis response to mitogens was studied. Porcine sera were obtained from pigs used in 2 different trials. In I trial, 4-wk-old pigs received either a basal diet deficient in vit E and Se or the basal diet supplemented with Vit E, Se or Vit E and Se. Pigs were maintained on their respective diet for 25 d. Canine sera were collected from pups maintained on a deficient diet for 8 wk. Four dogs and 4 pigs maintained on a commercial diet were used as donors of peripheral blood lymphocytes (PBL). The addition of sera from pigs or dogs maintained on a vit E- and Se-deficient diet markedly suppressed both porcine and canine PBL response to mitogens. Porcine PBL blastogenesis was also suppressed when porcine or canine sera were added 8, 24 or 48 h after the beginning of the incubation period to culture containing 1% of fetal bovine serum (FBS). However, the suppressive effect caused by porcine sera was less severe than the one due to canine sera. Addition of 1% FBS in the cultures was sufficient to eliminate the suppression caused by the presence of sera from pigs fed a vit E- and Se-deficient diet. Other attempts to restore the lymphocyte response to mitogens by the addition of indomethacin, diethylcarbamazine or eicosatetraynoic acid, inhibitors of prostaglandin and/or leukotriene synthesis, were not successful. Because of the severe suppression caused by sera from animals maintained on a vit E- and Se-deficient diet on the in vitro response of lymphocytes to mitogenic stimulations, it is very important to take precautions to avoid such deficiency. In vivo suppression of immunocompetent cells to antigenic stimulations may impair the capacity of the host to control infections.

5,8,11,14-Eicosatetraynoic Acid↗